SeleXel is a biotechnology company whose mission is to develop efficient therapeutic solutions in Oncology using a very innovative technology: RNA interference.
This natural biological mechanism allows to very specifically impair the synthesis of proteins required for the development of a cancer.
SeleXel concentrates its initial efforts on the development of drugs treating prostate cancers that became resistant to conventional hormonal treatments.
The company develops a portfolio of siRNAs blocking cancer spreading (metastasis), and restoring the ability of the immune system to eliminate the tumor.